Immunotargeting in the management of psoriasis
Benjamin H Kaffenberger,1 Thomas M Kaffenberger,2 Henry K Wong1 1College of Medicine, Ohio State University, Columbus, OH, USA; 2German Cancer Research Center (DKFZ), Heidelberg, Germany Abstract: The treatment of psoriasis has been revolutionized since the introduction of biologic therapies. Prior...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2013-07-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/immunotargeting-in-the-management-of-psoriasis-peer-reviewed-article-ITT |
| _version_ | 1818141903032418304 |
|---|---|
| author | Kaffenberger BH Kaffenberger TM Wong HK |
| author_facet | Kaffenberger BH Kaffenberger TM Wong HK |
| author_sort | Kaffenberger BH |
| collection | DOAJ |
| description | Benjamin H Kaffenberger,1 Thomas M Kaffenberger,2 Henry K Wong1 1College of Medicine, Ohio State University, Columbus, OH, USA; 2German Cancer Research Center (DKFZ), Heidelberg, Germany Abstract: The treatment of psoriasis has been revolutionized since the introduction of biologic therapies. Prior to their introduction, it was unclear if psoriasis was primarily a keratinocyte signaling dysfunction or an autoimmune T-cell mediated pathway. Nonspecific T-cell targeting treatments had been used with some success, but they were limited by a narrow therapeutic index. The nonspecific nature of these agents was fraught with side effects, and the efficacy of these treatments pales in comparison to current treatments. The initial biologic molecules, alefacept and efalizumab, were not specific for any T-cell driven pathway, and neither are currently available in the USA. The successors to these early therapies have shown high efficacy and low side effects in psoriasis and other autoimmune diseases through the specific targeting of tumor necrosis factor-alpha (TNF-α). Since the initial use of antitumor necrosis factor agents, a renaissance in our understanding of psoriasis has been underway, leading to the elucidation of the T-helper 17 (Th17) from the Th1 pathway. With each new treatment, the pathogenesis for psoriasis continues to be more defined, allowing for improved targeted therapies and the ability to achieve new milestones in efficacy. Keywords: psoriasis vulgaris, pathophysiology, immunology, T-cell signaling, biologic therapies, psoriasis treatment |
| first_indexed | 2024-12-11T11:07:16Z |
| format | Article |
| id | doaj.art-e6094c95e8924fe49dc5fe85035dc3ea |
| institution | Directory Open Access Journal |
| issn | 2253-1556 |
| language | English |
| last_indexed | 2024-12-11T11:07:16Z |
| publishDate | 2013-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ImmunoTargets and Therapy |
| spelling | doaj.art-e6094c95e8924fe49dc5fe85035dc3ea2022-12-22T01:09:40ZengDove Medical PressImmunoTargets and Therapy2253-15562013-07-012013Issue 1516013515Immunotargeting in the management of psoriasisKaffenberger BHKaffenberger TMWong HKBenjamin H Kaffenberger,1 Thomas M Kaffenberger,2 Henry K Wong1 1College of Medicine, Ohio State University, Columbus, OH, USA; 2German Cancer Research Center (DKFZ), Heidelberg, Germany Abstract: The treatment of psoriasis has been revolutionized since the introduction of biologic therapies. Prior to their introduction, it was unclear if psoriasis was primarily a keratinocyte signaling dysfunction or an autoimmune T-cell mediated pathway. Nonspecific T-cell targeting treatments had been used with some success, but they were limited by a narrow therapeutic index. The nonspecific nature of these agents was fraught with side effects, and the efficacy of these treatments pales in comparison to current treatments. The initial biologic molecules, alefacept and efalizumab, were not specific for any T-cell driven pathway, and neither are currently available in the USA. The successors to these early therapies have shown high efficacy and low side effects in psoriasis and other autoimmune diseases through the specific targeting of tumor necrosis factor-alpha (TNF-α). Since the initial use of antitumor necrosis factor agents, a renaissance in our understanding of psoriasis has been underway, leading to the elucidation of the T-helper 17 (Th17) from the Th1 pathway. With each new treatment, the pathogenesis for psoriasis continues to be more defined, allowing for improved targeted therapies and the ability to achieve new milestones in efficacy. Keywords: psoriasis vulgaris, pathophysiology, immunology, T-cell signaling, biologic therapies, psoriasis treatmenthttps://www.dovepress.com/immunotargeting-in-the-management-of-psoriasis-peer-reviewed-article-ITTpsoriasis vulgarispathophysiologyimmunologyT-cell signalingbiologic therapiespsoriasis treatment |
| spellingShingle | Kaffenberger BH Kaffenberger TM Wong HK Immunotargeting in the management of psoriasis ImmunoTargets and Therapy psoriasis vulgaris pathophysiology immunology T-cell signaling biologic therapies psoriasis treatment |
| title | Immunotargeting in the management of psoriasis |
| title_full | Immunotargeting in the management of psoriasis |
| title_fullStr | Immunotargeting in the management of psoriasis |
| title_full_unstemmed | Immunotargeting in the management of psoriasis |
| title_short | Immunotargeting in the management of psoriasis |
| title_sort | immunotargeting in the management of psoriasis |
| topic | psoriasis vulgaris pathophysiology immunology T-cell signaling biologic therapies psoriasis treatment |
| url | https://www.dovepress.com/immunotargeting-in-the-management-of-psoriasis-peer-reviewed-article-ITT |
| work_keys_str_mv | AT kaffenbergerbh immunotargetinginthemanagementofpsoriasis AT kaffenbergertm immunotargetinginthemanagementofpsoriasis AT wonghk immunotargetinginthemanagementofpsoriasis |